---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-038803"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2023-08-09T23:59:59+00:00"
generated_at: "2026-06-11T21:39:43.192120+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics raises FY2023 revenue guidance to >$240M; Q2 revenue up 77% to $60.1M

## Summary
- Q2 2023 total revenues $60.1M (+77% YoY); gross margin 27.8% (vs. 22.9% Q2 2022); normalized margin 31-32% excl. IT disruption.
- Adjusted EBITDA $6.4M vs. -$6.3M YoY; net loss narrowed to $6.4M from $13.8M; adjusted net loss $3.6M.
- FY2023 revenue guidance raised to at least $240M (from $220M); FY2024 raised to $275M; FY2025 to $325M+.
- Nonrecurring IT disruption charge of $2.8M in COGS; production has resumed; # of FDA-licensed plasma centers on track for 10 by year-end.
- Terminated financial advisory agreement with Morgan Stanley; continues to evaluate strategic alternatives.

## SEC filing metadata
- accession: 0001140361-23-038803
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2023-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/brhc20057230_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-038803
- JSON: https://secwatch.observer/filing/0001140361-23-038803.json
- Plain text: https://secwatch.observer/filing/0001140361-23-038803.txt

## Key facts
- Earnings Releases
  ADMA BIOLOGICS, INC. reported the three months ended June 30, 2023 results: revenue $60.1 Million. Guidance raised.
  - Period: the three months ended June 30, 2023
  - Revenue: $60.1 Million
  - Guidance: raised
  - Result: reported results
  source text: 2 brhc20057230_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update 2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA(1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss(2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm
- Earnings Releases
  ADMA BIOLOGICS, INC. reported FY2023 results: revenue $240 Million. Guidance raised.
  - Period: FY2023
  - Revenue: $240 Million
  - Guidance: raised
  - Result: guidance update
  source text: FY2023 Total Revenue Now Expected to Exceed $240 Million, Increased from $220 Million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm
- Earnings Releases
  ADMA BIOLOGICS, INC. reported FY2025 results: revenue $325 Million. Guidance raised.
  - Period: FY2025
  - Revenue: $325 Million
  - Guidance: raised
  - Result: guidance update
  source text: FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm
- Earnings Releases
  ADMA BIOLOGICS, INC. reported FY2024 results: revenue $275 Million. Guidance raised.
  - Period: FY2024
  - Revenue: $275 Million
  - Guidance: raised
  - Result: guidance update
  source text: FY2024 and 2025 Total Revenue Guidance Increased to $275 Million and $325 Million or More, Respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1368514/000114036123038803/0001140361-23-038803-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.